Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
About Us
News and Events
My HPRA:
Login
Register
About Us
Our Mission, Vision and Values
What We Regulate and How We Regulate
Our Strategic Plan 2021 – 2025
Contact Us
Our Structure
Patient Forum
Publications & Forms
Standards of Service
Privacy and Data Protection
Information and transparency
Consultations
Quality Management
Recruitment
Report an Issue
Legislation
Extranets
News and Events
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
HPRA working at EU level to remove/reduce MI in cosmetics
News Category:
Regulatory news
Date:
29/04/2015
The HPRA states that whilst the vast majority of consumers won’t have sensitivity to Methylisothiazolinone (MI) it is concerned about increased sensitivity to MI overall. The HPRA, in tandem with our colleagues across the other EU Member States, has been and is currently working with the European Commission on new laws to reduce the amount of MI permitted in cosmetic products.
HPRA Statement on Methylisothiazolinone
« Back
Date Printed: 06/05/2024